GeoVax Labs (NASDAQ:GOVX – Get Free Report) was upgraded by investment analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a note issued to investors on Saturday.
GOVX has been the topic of a number of other reports. D. Boral Capital reissued a “buy” rating and set a $9.00 target price on shares of GeoVax Labs in a report on Monday, June 16th. Alliance Global Partners decreased their target price on GeoVax Labs from $15.00 to $8.50 and set a “buy” rating on the stock in a report on Tuesday, April 15th. Finally, HC Wainwright reissued a “buy” rating and set a $8.00 target price on shares of GeoVax Labs in a report on Wednesday, April 16th. One analyst has rated the stock with a hold rating, five have assigned a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $11.10.
Read Our Latest Stock Report on GeoVax Labs
GeoVax Labs Trading Up 2.1%
GeoVax Labs (NASDAQ:GOVX – Get Free Report) last posted its earnings results on Thursday, May 1st. The company reported ($0.45) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.59) by $0.14. The business had revenue of $1.64 million for the quarter, compared to analyst estimates of $0.75 million. GeoVax Labs had a negative return on equity of 511.96% and a negative net margin of 438.20%. As a group, sell-side analysts predict that GeoVax Labs will post -4.49 EPS for the current fiscal year.
Institutional Trading of GeoVax Labs
Several institutional investors have recently added to or reduced their stakes in GOVX. Jane Street Group LLC bought a new stake in GeoVax Labs in the 1st quarter valued at $27,000. Northern Trust Corp bought a new stake in GeoVax Labs in the 4th quarter valued at $29,000. Citadel Advisors LLC bought a new stake in GeoVax Labs in the 4th quarter valued at $104,000. Geode Capital Management LLC lifted its position in shares of GeoVax Labs by 59.0% during the 4th quarter. Geode Capital Management LLC now owns 90,139 shares of the company’s stock valued at $223,000 after acquiring an additional 33,440 shares during the period. Finally, Armistice Capital LLC acquired a new stake in shares of GeoVax Labs during the 1st quarter worth $703,000. 6.09% of the stock is currently owned by institutional investors.
About GeoVax Labs
GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.
See Also
- Five stocks we like better than GeoVax Labs
- REIT Stocks – Best REIT Stocks to Add to Your Portfolio Today
- New All-Time Highs Coming for Broadcom? Wall Street Says Yes
- Why Are These Companies Considered Blue Chips?
- Overheated Market? Analysts Watch These Red Flags
- Dividend King Proctor & Gamble Is A Buy On Post-Earnings Weakness
- 3 Reasons AMD Could Be the Hottest Stock of the Summer
Receive News & Ratings for GeoVax Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GeoVax Labs and related companies with MarketBeat.com's FREE daily email newsletter.